Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TruSpine Technologies Plc AGM Information 2022

Oct 31, 2022

10307_pos_2022-10-31_ea355f76-914f-451a-897d-4a876b66e1d6.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 7456E

TruSpine Technologies PLC

31 October 2022

TruSpine Technologies plc

("TruSpine" or the "Company")

Further re AGM

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the development of its pioneering "screwless," spinal (vertebral) stabilisation systems, announces that, further to the announcement released on 27 October 2022, its Annual General Meeting ("AGM") was adjourned until further notice. The adjournment was approved by way of a majority shareholder vote present at the AGM, through a show of hands, and without any business being conducted. 

Enquiries:

Truspine Technologies Plc Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)

Lucy Williams / Duncan Vasey
Tel: +44 (0)20 7469 0930
Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy [email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFEIILLLVIF